CORDIS
EU research results

CORDIS

English EN

Cultivated Adult Stem Cells as Alternative for Damaged tissue

Objective

Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The objective of CASCADE is to provide the European Community with unique expertise which focuses on the GMP production of mesenchymal stem cells (MSC) and their use in treating skin and corneal wounds, so that quality and safety criteria are paramount and match therapeutic expectations. Commencing with known procedures, CASCADE will develop innovative technologies based on the expertise of its partners. Among our research themes, the specific issue of multiple recipients and universal donors will be investigated. To this end, human MSC will be derived from 4 tissues, bone marrow, fat tissue, cord blood and amniotic membrane, according to good manufacturing practice (GMP). Phenotypic identity of GMP produced MSC, their genetic status and their potential for transformation will constitute the basis for establishing standards for controlling cell production. The efficacy of GMP produced MSC will be tested in in vitro and in vivo models, and the immunological consequences of their use will be studied. Moreover, during the whole CASCADE initiative, ethical and legal issues raised as a result of MSC therapies will be considered. Direct collaboration with two clinical networks will allow CASCADE to finely tune production specifications, and define optimal clinical protocols for these MSC-based cellular therapies. CASCADE will therefore gather together leading European cell therapy laboratories with unrivalled expertise in the production of therapeutic cells and in MSC biology, four SMEs with specific know-how in GMP production of cells and two clinical networks in dermatology and ophthalmology. The outcome will be a consortium that encompasses all the technologies and skills required to efficiently develop innovative technologies for the production of clinical grade MSC and to translate this production into a cell drug to repair wounds.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ETABLISSEMENT FRANCAIS DU SANG

Address

Avenue Du Stade De France 20
93210 La Plaine Saint Denis

France

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

EU Contribution

€ 430 000

Administrative Contact

Laurent Beauverger (Mr.)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH

Germany

EU Contribution

€ 599 414

FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO

Italy

EU Contribution

€ 204 578

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 243 725

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 115 243

UNIVERSITA DEGLI STUDI DI VERONA

Italy

EU Contribution

€ 152 800

UNIVERSITATEA DE MEDICINA SI FARMACIE VICTOR BABES TIMISOARA

Romania

EU Contribution

€ 132 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 143 000

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 80 000

ABCELL-BIO Sarl

France

EU Contribution

€ 135 000

ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT

France

EU Contribution

€ 74 999

BIOTRACK SRL

Italy

EU Contribution

€ 120 249

UNIVERSITAT DES SAARLANDES

Germany

EU Contribution

€ 123 000

UNIVERSITAET ULM

Germany

EU Contribution

€ 142 798

UNIVERSITAETSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 83 000

ALCIMED

France

EU Contribution

€ 199 861

Project information

Grant agreement ID: 223236

Status

Closed project

  • Start date

    1 January 2009

  • End date

    31 December 2011

Funded under:

FP7-HEALTH

  • Overall budget:

    € 5 130 179

  • EU contribution

    € 2 979 667

Coordinated by:

ETABLISSEMENT FRANCAIS DU SANG

France